Edward J Brnardic

USPTO Granted Patents = 8 (Patent Applications = 4)

EPO Patents = 3 (Patent Applications = 7)

Average Co-Inventor Count = 5.1

ph-index = 3

Forward Citations = 23(Granted Patents)

Company Filing History:

5 out of 2,405

Merck Sharp + Dohme Corp.

Years Active: 2009-2023

Loading Chart...

8 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11655216 - Aryl and heteroaryl ether derivatives as liver X receptor beta agonists, compositions, and their use (2023-05-23),

2. 10961215 - N-aryl and N-heteroaryl piperidine derivatives as liver X receptor beta agonists, compositions, and their use (2021-03-30),

3. 10894775 - Piperidine derivatives as liver X receptor beta agonists, compositions, and their use (2021-01-19),

4. 10239849 - Cyanopyridine derivatives as liver X receptor beta agonists, compositions, and their use (2019-03-26),

5. 9181261 - TrkA kinase inhibitors, compositions and methods thereof (2015-11-10),

6. 7550477 - Inhibitors of checkpoint kinases (2009-06-23),

7. 7501435 - Inhibitors of checkpoint kinases (2009-03-10),

8. 7485649 - Inhibitors of checkpoint kinases (2009-02-03),

Title: The Inventive Mind of Edward J Brnardic: Revolutionizing Pharmaceutical Treatments

Introduction:

Edward J Brnardic, a talented inventor hailing from Lansdale, PA, has made a significant mark in the field of pharmaceuticals with a total of 8 patents to his name. His innovative work has been recognized for its potential in treating a range of pathologies, including inflammatory diseases and conditions linked to cholesterol and lipid metabolism.

Latest Patents:

Among his latest patents is the groundbreaking invention of aryl and heteroaryl ether derivatives as liver X receptor beta agonists. These compounds, along with N-aryl and N-heteroaryl piperidine derivatives, have shown promise in the realm of medicinal treatments, particularly in addressing diseases such as Alzheimer's.

Career Highlights:

Edward J Brnardic has carved a path of success through his tenure at esteemed pharmaceutical companies like Merck Sharp & Dohme Corporation and Merck & Company, Inc. His expertise and dedication have led to the development of novel pharmaceutical compounds that hold immense potential in the treatment of complex medical conditions.

Collaborations:

Throughout his career, Edward J Brnardic has collaborated with a host of talented individuals, including coworkers like Shawn J Stachel and Michael T Rudd. These collaborations have been instrumental in bringing his inventive concepts to fruition and advancing the field of pharmaceutical research.

Conclusion:

In conclusion, Edward J Brnardic stands as a beacon of innovation in the pharmaceutical industry, with his patents paving the way for novel treatment modalities. His contributions have the potential to address critical health issues and make a lasting impact on the lives of many.

This text is generated by artificial intelligence and may not be accurate.